PACT Pharma clinical stage biotechnology company developing personalized adoptive T cell therapies for the eradication of solid tumors.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/30/2022 | Series D | $104.1MM | $xx.xx | $132.98MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,557,208,727
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Undisclosed Investors
|
||||||
06/15/2020 | Series C-1 | $50MM | $xx.xx | $514.44MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
17,806,901
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
01/10/2020 | Series C | $75MM | $xx.xx | $297.64MM | Vida Ventures, GV, Canaan, Casdin Capital, Droia, Foresite Capital, Invus Opportunities, Pontifax, Wu Capital | |
Price per Share
$xx.xx
Shares Outstanding
36,642,564
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Vida Ventures, GV, Canaan, Casdin Capital, Droia, Foresite Capital, Invus Opportunities, Pontifax, Wu Capital
|
||||||
05/25/2018 | Series B | $95.5MM | $xx.xx | $182.24MM | GV, Canaan Partners, AbbVie Ventures, Casdin Capital, DROIA, Foresite Capital, Invus, Pontifax, Taiho Ventures, Wu Capital | |
Price per Share
$xx.xx
Shares Outstanding
56,963,913
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
GV, Canaan Partners, AbbVie Ventures, Casdin Capital, DROIA, Foresite Capital, Invus, Pontifax, Taiho Ventures, Wu Capital
|
||||||
12/20/2016 | Series A | $30MM | $xx.xx | $46.15MM | GV | |
Price per Share
$xx.xx
Shares Outstanding
29,999,999
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
GV
|